Veristat, a full service clinical research organization (CRO), has signed a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. Veristat has assisted Aegerion with FDA, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years. Veristat will offer Aegerion clinical trial support including statistical consulting, ...